PERSONALIS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.395 USD | -2.45% |
|
-15.45% | -33.57% |
| May. 08 | Transcript : Personalis, Inc., Q1 2024 Earnings Call, May 08, 2024 | |
| May. 08 | Earnings Flash (PSNL) PERSONALIS Reports Q1 Revenue $19.5M, vs. Street Est of $18.4M | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 76.96M | Sales 2025 * | 84.8M | Capitalization | 71.44M |
|---|---|---|---|---|---|
| Net income 2024 * | -72M | Net income 2025 * | -72M | EV / Sales 2024 * | 0.7 x |
| Net cash position 2024 * | 17.59M | Net cash position 2025 * | 107M | EV / Sales 2025 * | -0.42 x |
| P/E ratio 2024 * |
-0.99
x | P/E ratio 2025 * |
-1.04
x | Employees | 224 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.2% |
More Fundamentals
* Assessed data
More news
Latest transcript on Personalis, Inc.
More recommendations
More press releases
More news
| 1 day | -2.45% | ||
| 1 week | -15.45% | ||
| Current month | -5.10% | ||
| 1 month | +12.50% | ||
| 3 months | +2.57% | ||
| 6 months | +35.44% | ||
| Current year | -33.57% |
1 week
1.32
1.69
1 month
1.181.85
Current year
1.122.35
1 year
0.892.60
3 years
0.8928.47
5 years
0.8953.46
10 years
0.8953.46
| Managers | Title | Age | Since |
|---|---|---|---|
Christopher Hall
CEO | Chief Executive Officer | 55 | 22-10-30 |
Aaron Tachibana
DFI | Director of Finance/CFO | 63 | 19-02-28 |
Richard Chen
CTO | Chief Tech/Sci/R&D Officer | 53 | 11-10-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Arthur Bowman
BRD | Director/Board Member | 77 | 19-04-30 |
Kenneth Widder
BRD | Director/Board Member | 71 | 23-06-13 |
Woodrow Myers
BRD | Director/Board Member | 70 | 21-03-05 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.67% | 0 M€ | 0.00% | - | |
| 0.08% | 115 M€ | +5.44% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-16 | 1.395 | -2.45% | 172,093 |
| 24-05-15 | 1.43 | -5.92% | 225,346 |
| 24-05-14 | 1.52 | -1.30% | 264,181 |
| 24-05-13 | 1.54 | -1.91% | 260,708 |
| 24-05-10 | 1.57 | -4.85% | 134,137 |
Delayed Quote Nasdaq, May 16, 2024 at 04:00 pm EDT
More quotes
Personalis, Inc. is engaged in developing and marketing advanced cancer genomic tests and analytics. The Companyâs advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other next generation cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome sequencing (WGS). NeXT Personal is a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer. NeXT Dx is a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. The Company performed WGS on human samples for research projects, such as population sequencing initiatives. The Companyâs tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, the development of personalized cancer therapies.
Calendar
12:00pm
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
1.395
USD
Average target price
4.6
USD
Spread / Average Target
+229.75%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -33.57% | 73.23M | |
| +33.37% | 49.46B | |
| +1.55% | 42.58B | |
| +49.11% | 42.49B | |
| -4.22% | 29.09B | |
| +11.57% | 26.61B | |
| -21.00% | 18.64B | |
| +7.36% | 13.16B | |
| +28.30% | 12.55B | |
| +23.80% | 12.1B |
- Stock Market
- Equities
- PSNL Stock